Inventor · disambiguated record
James P. Fandl
Also filed as: FANDL JAMES · FANDL JAMES P
65 granted patents·19 pending applications·2,227 citations·filing 1991–2024
99Inventor score
Top patents by PatentIndex Score
84 records- 0199US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 0299US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 0399US7435553B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2006·Granted Oct 14, 2008·104 cites·15 claims
- 0499US7306799B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 11, 2007·140 cites·11 claims
- 0599US7303747B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 4, 2007·112 cites·6 claims
- 0699US7087411B2Fusion protein capable of binding VEGFREGENERON PHARMA·Filed 2003·Granted Aug 8, 2006·345 cites·16 claims
- 0798US7972598B2VEGF-binding fusion proteins and therapeutic uses thereofREGENERON PHARMA·Filed 2009·Granted Jul 5, 2011·76 cites·1 claims
- 0898US7635474B2VEGF-binding fusion proteinsREGENERON PHARMA·Filed 2008·Granted Dec 22, 2009·77 cites·4 claims
- 0998US7521049B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2007·Granted Apr 21, 2009·74 cites·15 claims
- 1098US7399612B2VEGF-binding fusion proteins and nucleic acids encoding the sameREGENERON PHARMA·Filed 2006·Granted Jul 15, 2008·58 cites·7 claims
- 1198US7279159B2VEGF inhibitor polypeptidesREGENERON PHARMA·Filed 2004·Granted Oct 9, 2007·191 cites·8 claims
- 1297US9816110B2CHO integration sites and uses thereofREGENERON PHARMA·Filed 2015·Granted Nov 14, 2017·19 cites·29 claims
- 1397US7771997B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2008·Granted Aug 10, 2010·55 cites·8 claims
- 1497US6919183B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2002·Granted Jul 19, 2005·88 cites·47 claims
- 1596US9884916B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2016·Granted Feb 6, 2018·13 cites·7 claims
- 1695US8597898B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2012·Granted Dec 3, 2013·16 cites·22 claims
- 1795US8409838B2Fucosylation-deficient cellsCHEN GANG·Filed 2010·Granted Apr 2, 2013·18 cites·12 claims
- 1895US8389239B2Enhanced expression and stability regionsCHEN GANG·Filed 2010·Granted Mar 5, 2013·17 cites·20 claims
- 1995US7534604B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2005·Granted May 19, 2009·41 cites·9 claims
- 2094US8927233B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2013·Granted Jan 6, 2015·16 cites·34 claims
- 2194US8865430B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2013·Granted Oct 21, 2014·16 cites·15 claims
- 2294US8192741B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2011·Granted Jun 5, 2012·22 cites·10 claims
- 2393US11808766B2Method for generating high affinity antibodiesREGENERON PHARMA·Filed 2020·Granted Nov 7, 2023·2 cites·47 claims
- 2493US8568721B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2012·Granted Oct 29, 2013·18 cites·9 claims
- 2593US2025206829A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2692US10752698B2Method for generating high affinity antibodiesREGENERON PHARMA·Filed 2015·Granted Aug 25, 2020·5 cites·26 claims
- 2792US8470324B2Fusion polypeptides capable of activating receptorsREENERON PHARMACEUTICALS INC·Filed 2012·Granted Jun 25, 2013·18 cites·20 claims
- 2892US8298532B2Fusion polypeptides capable of activating receptorsFANDL JAMES P·Filed 2009·Granted Oct 30, 2012·19 cites·20 claims
- 2992US8183014B2High affinity antibodies to human IL-6 receptorSTEVENS SEAN·Filed 2011·Granted May 22, 2012·11 cites·19 claims
- 3091US9308256B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·11 cites·14 claims
- 3191US8080248B2Method of treating rheumatoid arthritis with an IL-6R antibodyRADIN ALLEN·Filed 2010·Granted Dec 20, 2011·15 cites·11 claims
- 3291US7455988B2Inducible eukaryotic expression systemREGENERON PHARMA·Filed 2003·Granted Nov 25, 2008·33 cites·11 claims
- 3390US9732357B2Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2015·Granted Aug 15, 2017·3 cites·41 claims
- 3489US11268109B2CHO integration sites and uses thereofREGENERON PHARMA·Filed 2021·Granted Mar 8, 2022·1 cites·15 claims
- 3589US9550823B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2015·Granted Jan 24, 2017·2 cites·13 claims
- 3689US9222106B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2013·Granted Dec 29, 2015·4 cites·32 claims
- 3789US9206455B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2013·Granted Dec 8, 2015·4 cites·12 claims
- 3889US8673589B2Inducible eukaryotic expression systemCHEN GANG·Filed 2008·Granted Mar 18, 2014·8 cites·4 claims
- 3988US12480947B2Method for generating high affinity antibodiesREGENERON PHARMA·Filed 2023·Granted Nov 25, 2025·0 cites·20 claims
- 4086US12054751B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·12 claims
- 4186US11370843B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2020·Granted Jun 28, 2022·1 cites·15 claims
- 4286US10598669B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2019·Granted Mar 24, 2020·1 cites·20 claims
- 4386US9469856B2Inducible eukaryotic expression systemREGENERON PHARMA·Filed 2014·Granted Oct 18, 2016·4 cites·20 claims
- 4486US9389236B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2013·Granted Jul 12, 2016·3 cites·34 claims
- 4585US11530277B2Compositions and methods for making antibodies based on use of an expression-enhancing locusREGENERON PHARMA·Filed 2017·Granted Dec 20, 2022·2 cites·41 claims
- 4685US10457959B2Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2017·Granted Oct 29, 2019·2 cites·33 claims
- 4785US7514545B2Inducible eukaryotic expression systemREGENERON PHARMA·Filed 2006·Granted Apr 7, 2009·6 cites·5 claims
- 4884US11085053B2Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2019·Granted Aug 10, 2021·1 cites·9 claims
- 4983US2023094591A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 5082US10006070B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2016·Granted Jun 26, 2018·1 cites·20 claims
Showing the top 50 of 84 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when James P. Fandl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →